Assisting smokers to achieve tobacco cessation has always been difficult. The development of pharmacological approaches to the attainment of abstinence from tobacco usage has been very helpful, although our understanding of optimal clinical use is still incomplete and imperfect. Bupropion and nicotine therapy (NT) will help reduce the severity of nicotine withdrawal symptoms, whether used separately or in combination. Effectiveness is greater with the combination of drugs than with either drug alone. Nevertheless, the initial ‘quit rate’ is usually less than 50%, and there is a considerable decrease in the abstinence rate after the course of therapy has been completed. Effectiveness is increased if higher doses of NT are employed, with or without concomitant bupropion. Much remains to be learned about optimal doses, preferred durations of therapy and tapering, prevention and management of relapses, and selection of modes of delivery of NT. The discovery that nicotine dependence has a major genetic component has stimulated much interest and many research studies. The preliminary results are interesting, to say the least.

1.
Fagerström KO: A comparison of psychological and pharmacological treatment in smoking cessation. J Behav Med 1982;5:343–351.
2.
Lillington GA, Leonard CT, Sachs DP: Smoking cessation: Techniques and benefits. Clin Chest Med 2000;21:199–208.
3.
A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. JAMA 2000;283:3244–3254.
4.
Silagy C, Mant D, Fowler G, Lancaster T: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2000;3:CD000146.
5.
Silagy C, Mant D, Fowler G, Lodge M: Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet 1994;343:139–142.
6.
Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB: A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340:685–691.
7.
Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, Croghan IT, Sullivan PM: A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997;337:1195–1202.
8.
Fragerström KO: Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav 1978;3:235–241.
9.
Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO: The Fagerström Test for Nicotine Dependence: A revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991;86:1119–1127.
10.
Tonnesen P, Paoletti P, Gustavsson G, Russell MA, Saracci R, Gulsvik A, Rijcken B, Sawe U: Higher dosage nicotine patches increase one-year smoking cessation rates: Results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. Eur Respir J 1999;13:238–246.
11.
Daughton DM, Fortmann SP, Glover ED, Hatsukami DK, Heatley SA, Lichtenstein E, Repsher L, Millatmal T, Killen JD, Nowak RT, Ullrich F, Patil KD, Rennard SI: The smoking cessation efficacy of varying doses of nicotine patch delivery systems 4 to 5 years post-quit day. Prev Med 1999;28:113–118.
12.
Blondal T, Gudmundsson LJ, Olafsdottir I, Gustavsson G, Westin A: Nicotine nasal spray with nicotine patch for smoking cessation: Randomised trial with six year follow up. BMJ 1999;318:285–288.
13.
Dale LC, Hurt RD, Offord KP, Lawson GM, Croghan IT, Schroeder DR: High-dose nicotine patch therapy: Percentage of replacement and smoking cessation. JAMA 1995;274:1353–1358.
14.
Fredrickson PA, Hurt RD, Lee GM, Wingender L, Croghan IT, Lauger G, Gomez-Dahl L, Offord KP: High dose transdermal nicotine therapy for heavy smokers: Safety, tolerability and measurement of nicotine and cotinine levels. Psychopharmacology (Berl) 1995;122:215–222.
15.
Bolliger CT, Zellweger JP, Danielsson T, van Biljon X, Robidou A, Westin A, Perruchoud AP, Sawe U: Smoking reduction with oral nicotine inhalers: Double blind, randomised clinical trial of efficacy and safety. BMJ 2000;321:329–333.
16.
Benowitz NL (ed): Nicotine Safety and Toxicity. New York, Oxford University Press, 1998.
17.
Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele BG, Sherman SE, Cleveland M, Antonnucio DO, Hartman N, McGovern PG: The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996;335:1792–1798.
18.
Sachs DPL, Benowitz NL, Bostrom AG, Hansen MD: Percent serum replacement and success of nicotine patch therapy. Am J Respir Crit Care Med 1995;151:A688.
19.
Lancaster T, Stead LF: Mecamylamine (a nicotine antagonist) for smoking cessation (review). Cochrane Database Syst Rev 2000;2:CD001009.
20.
Hughes JR: Genetics of smoking: A brief review. Behav Ther 1986;17:335–345.
21.
Walton R, Johnstone E, Munafo M, Neville M, Griffiths S: Genetic clues to the molecular basis of tobacco addiction and progress towards personalized therapy. Trends Mol Med 2001;7:70–76.
22.
Pitarque M, von Richter O, Oke B, Berkkan H, Oscarson M, Ingelman-Sundberg M: Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: Impairment of its promoter activity. Biochem Biophys Res Commun 2001;284:455–460.
23.
Comings DE, Ferry L, Bradshaw-Robinson S, Burchette R, Chiu C, Muhleman D: The dopamine D2 receptor (DRD2) gene: A genetic risk factor in smoking. Pharmacogenetics 1996;6:73–79.
24.
Lebargy F, Benhammou K, Morin D, Zini R, Urien S, Bree F, Bignon J, Branellec A, Lagrue G: Tobacco smoking induces expression of very-high-affinity nicotine binding sites on blood polymorphonuclear cells. Am J Respir Crit Care Med 1996;153:1056–1063.
25.
Heeschen C, Jang JJ, Weis M, Pathak A, Kaji S, Hu RS, Tsao PS, Johnson FL, Cooke JP: Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med 2001;7:833–839.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.